Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses Kreutzer-Limmer RNAi Patents to Bioneer

NEW YORK, May 24 (GenomeWeb News) - Alnylam Pharmaceuticals will license its RNAi research products to Bioneer, the company said today.


The non-exclusive license is for products under the Kreutzer-Limmer patent family, which covers small interfering RNAs and their use to mediate RNAi in mammalian cells. Alnylam is the exclusive owner of these patents.


Financial details were not disclosed.